105 related articles for article (PubMed ID: 33471346)
1. Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study.
Leong C; Czaykowski P; Geirnaert M; Katz A; Dragan R; Yogendran M; Raymond C
Can J Public Health; 2021 Jun; 112(3):530-540. PubMed ID: 33471346
[TBL] [Abstract][Full Text] [Related]
2. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
Wheeler SB; Spees LP; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Dinan MA
JCO Oncol Pract; 2021 Dec; 17(12):e1895-e1904. PubMed ID: 34138665
[TBL] [Abstract][Full Text] [Related]
3. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.
Wilson LE; Spees L; Pritchard J; Greiner MA; Scales CD; Baggett CD; Kaye D; George DJ; Zhang T; Wheeler SB; Dinan MA
Kidney Cancer; 2021; 5(3):115-127. PubMed ID: 34632169
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
5. How adverse events and permanent medication stoppages affect changes in patients' beliefs about oral antineoplastic agents.
Marshall VK; Given CW; Sikorskii A; Given BA; Lehto RH
Support Care Cancer; 2020 Jun; 28(6):2589-2596. PubMed ID: 31529159
[TBL] [Abstract][Full Text] [Related]
6. Medication Adherence Among Adults With Comorbid Chronic Conditions Initiating Oral Anticancer Agent Therapy for Multiple Myeloma.
Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
JCO Oncol Pract; 2022 Sep; 18(9):e1475-e1483. PubMed ID: 35700416
[TBL] [Abstract][Full Text] [Related]
7. Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population-based cohort study.
Alkabbani W; Marrie RA; Bugden S; Alessi-Severini S; Bolton JM; Daeninck P; Leong C
Addiction; 2019 Oct; 114(10):1791-1799. PubMed ID: 31240747
[TBL] [Abstract][Full Text] [Related]
8. Outpatient cancer drug costs: changes, drivers, and the future.
Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
[TBL] [Abstract][Full Text] [Related]
9. The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada.
Righolt CH; Pabla G; Mahmud SM
Appl Health Econ Health Policy; 2018 Apr; 16(2):195-205. PubMed ID: 29299769
[TBL] [Abstract][Full Text] [Related]
10. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study.
Ko Y; Tan SL; Chan A; Wong YP; Yong WP; Ng RC; Lim SW; Salim A
Clin Ther; 2012 Aug; 34(8):1696-704. PubMed ID: 22795926
[TBL] [Abstract][Full Text] [Related]
12. Rising Cost of Anticancer Medications in the United States.
Jackson K; Nahata MC
Ann Pharmacother; 2017 Aug; 51(8):706-710. PubMed ID: 28707550
[TBL] [Abstract][Full Text] [Related]
13. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
[TBL] [Abstract][Full Text] [Related]
14. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006.
Alessi-Severini S; Biscontri RG; Collins DM; Kozyrskyj A; Sareen J; Enns MW
Psychiatr Serv; 2008 May; 59(5):547-53. PubMed ID: 18451015
[TBL] [Abstract][Full Text] [Related]
15. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
[TBL] [Abstract][Full Text] [Related]
17. Implementation of a model integrating primary and oncology pharmacists' care for patients taking oral anticancer agents (OAA).
Farris KB; Cadwallader T; Farley J; Gatwood K; Mackler E; Gatwood J
Explor Res Clin Soc Pharm; 2022 Sep; 7():100163. PubMed ID: 35957656
[TBL] [Abstract][Full Text] [Related]
18. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.
Metge CJ; Blanchard JF; Peterson S; Bernstein CN
Am J Gastroenterol; 2001 Dec; 96(12):3348-55. PubMed ID: 11774948
[TBL] [Abstract][Full Text] [Related]
19. Photo elicitation, an approach to better understanding the patient experience with OAAs: pilot study and future implications.
Manojlovich M; Blok A; Wright N; Azhari E; Farris KB; Friese CR; Mackler E; Titler M; Byrnes M
Support Care Cancer; 2023 Oct; 31(12):652. PubMed ID: 37878093
[TBL] [Abstract][Full Text] [Related]
20. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study.
Patel C; Emond B; Morrison L; Lafeuille MH; Lefebvre P; Lin D; Kim E; Joshi K
Curr Med Res Opin; 2021 Apr; 37(4):665-674. PubMed ID: 33507831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
